Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 7/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30414619 | 1.00 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1PTK2CYP2A6CYP3A4 | |
| SCHEMBL27854767 | 0.89 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1PTK2CYP2A6CYP3A4 | |
| SCHEMBL27735989 | 0.89 | CYP2A6 (0.54) | HSP90AA1HSP90AB1PTK2CYP2A6CYP3A4 | |
| SCHEMBL27735998 | 0.83 | PIM1 (0.46) | HSP90AA1HSP90AB1PTK2CYP2A6CYP3A4 | |
| SCHEMBL934072 | 0.79 | FEN1 (0.62) | HSP90AA1ALOX5APFEN1 | |
| SCHEMBL29817861 | 0.79 | FEN1 (0.62) | HSP90AA1ALOX5APFEN1 | |
| SCHEMBL27736012 | 0.78 | MAPK1 (0.44) | HSP90AA1ALDH1A1CYP2D6MAPK1ALOX5AP | |
| SCHEMBL14970102 | 0.77 | CYP2A6 (0.62) | HSP90AA1HSP90AB1PTK2CYP2A6CYP3A4 | |
| SCHEMBL19556283 | 0.77 | CYP2A6 (0.53) | HSP90AA1HSP90AB1PTK2CYP2A6CYP3A4 | |
| SCHEMBL15106517 | 0.77 | CYP2A6 (0.62) | HSP90AA1HSP90AB1PTK2CYP2A6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750880-B1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2022-12-21 | — | — | EP | disclosed |
| US-11434245-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-09-06 | — | — | US | disclosed |
| US-11434245-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-09-06 | — | — | US | disclosed |
| US-11286248-B2 | Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2022-03-29 | — | — | US | disclosed |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-18 | — | — | US | disclosed |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-18 | — | — | US | disclosed |
| US-20210040070-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| US-10870653-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-22 | — | — | US | disclosed |
| US-10870653-B2 | WNT pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-22 | — | — | US | disclosed |
| EP-3750880-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2020-12-16 | — | — | EP | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | HSP90AA1 4163/4885HSP90AB1 4032/4885PTK2 3244/4885 |
| US-20210040070-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | FGFR1, FGFR2, FGFR3 | HSP90AA1 778/4885HSP90AB1 508/4885PTK2 157/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | HSP90AA1 4163/4885HSP90AB1 4032/4885PTK2 3244/4885 |
| US-11434245-B2 | WNT pathway modulators | WNT1, WNT3A, WNT3 | HSP90AA1 3518/4885HSP90AB1 2347/4885PTK2 797/4885 |
| US-10870653-B2 | WNT pathway modulators | WNT1, WNT3A, WNT3 | HSP90AA1 4499/4885HSP90AB1 3935/4885PTK2 1140/4885 |
| US-20210047336-A1 | WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | HSP90AA1 3219/4885HSP90AB1 2424/4885PTK2 1560/4885 |
| US-11286248-B2 | Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor | FGFR1, FGFR2, FGFR3 | HSP90AA1 778/4885HSP90AB1 508/4885PTK2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.